H. Curé - Concepedia

Author

H. Curé

Centre Jean Perrin

Also Known As

H Cure, H Curé, H Curé, H Cúre, H. Cure, H. Curé, Hector Cure, Hector W. Cure, Héctor Cure, J.F. Héron

147

Publications

2.9K

Citations

H-Index

Concepts

All Affiliations

Centre Jean Perrin Inserm Centre Léon Bérard Institut Curie Institut Claudius Regaud

About

H. Curé is an author at Centre Jean Perrin specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	25	1.6K
2	Health Sciences	4	4	233
3	Public Health	1	1	156
4	Blood Transplantation	1	1	20
5	Cell Biology	1	1	51

H. Curé

Publications

2.4K

Citations

H-Index

Page 1

	Year	Citations
Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer P. Fumoleau, R. Largillier, Christine Clippe, European Journal of Cancer Breast OncologyOncologyMedicinePhase Ii StudyBreast Cancer	2003	307
Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer P. Chollet, S. Amat, H. Curé, British Journal of Cancer	2002	255
Validation of the G8 screening tool in geriatric oncology: The ONCODAGE project. Pierre Soubeyran, Carine Bellera, Jean Goyard, Journal of Clinical Oncology Cancer ManagementEpidemiology Of CancerPathologyScreening ToolOncology	2011	156
Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer P. Chollet, M.A. Bensmaïne, S. Brienza, Annals of Oncology OncologyMedicinePharmacologyGynecologyAnti-cancer Agent	1996	140
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial Xavier Pivot, Gilles Romieu, Marc Debled, The Lancet Breast OncologyOncologyEarly Breast CancerRandomised TrialBreast Cancer	2019	125
Clinical and pathological response to primary chemotherapy in operable breast cancer P. Chollet, Sabine Charrier, Étienne Brain, European Journal of Cancer Surgical OncologyBreast OncologyMedicinePathologyPathological Response	1997	121
Scarff-Bloom-Richardson (SBR) grading: a pleiotropic marker of chemosensitivity in invasive ductal breast carcinomas treated by neoadjuvant chemotherapy S. Amat, Frédérique Penault‐Llorca, H. Curé, International Journal of Oncology Pleiotropic MarkerSurgical OncologyBreast OncologyNeoadjuvant ChemotherapyMedicine	2002	116
Phase II trial with S-1 in chemotherapy-naıve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG) P. Chollet, Patrick Schöffski, K. Weigang-Köhler, European Journal of Cancer	2003	106
High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: long-term results. Michel Legros, J Dauplat, J Fleury, Journal of Clinical Oncology	1997	97
Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate S. Amat, Philippe Bougnoux, Frédérique Penault‐Llorca, British Journal of Cancer	2003	91

Page 1